Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term effectiveness and tolerability of apremilast in patients with moderate-to-severe plaque psoriasis: A 5-year multicentre retrospective study-IL PSO (Italian landscape psoriasis).
Gargiulo L, Ibba L, Malagoli P, Amoruso F, Balato A, Bardazzi F, Burlando M, Carrera CG, Dapavo P, Dini V, Gaiani FM, Girolomoni G, Guarneri C, Lasagni C, Loconsole F, Marzano AV, Maurelli M, Megna M, Travaglini M, Costanzo A, Narcisi A. Gargiulo L, et al. Among authors: travaglini m. J Eur Acad Dermatol Venereol. 2024 Mar 29. doi: 10.1111/jdv.20003. Online ahead of print. J Eur Acad Dermatol Venereol. 2024. PMID: 38553873 No abstract available.
Treatment of psoriasis with different dosage regimens of etanercept: preliminary results from the Tαranta Plastic Study Group.
Cassano N, Loconsole F, Miracapillo A, Travaglini M, Digiuseppe MD, Congedo M, Galluccio A, Buquicchio R, Mastrandrea V, Filieri M, Raho G, Pezza M, Vena GA. Cassano N, et al. Among authors: travaglini m. Int J Immunopathol Pharmacol. 2010 Jul-Sep;23(3):797-802. doi: 10.1177/039463201002300314. Int J Immunopathol Pharmacol. 2010. PMID: 20943050 Free article. Clinical Trial.
Assessing the Beneficial Impact of a Patient Support Program in Secukinumab-Treated Patients with Psoriasis in Italy.
Argenziano G, Amerio P, Aragone MG, Baggini G, Baldari M, Castelli G, Coppola S, Costanzo A, De Pasquale R, Fargnoli MC, Foti C, Giofrè C, Lembo S, Leporati C, Loconsole F, Malara G, Peris K, Richetta AG, Savoia P, Tiberio R, Travaglini M, Uzzauto MT, Bianchi L. Argenziano G, et al. Among authors: travaglini m. Patient Prefer Adherence. 2021 Nov 19;15:2551-2562. doi: 10.2147/PPA.S326498. eCollection 2021. Patient Prefer Adherence. 2021. PMID: 34824526 Free PMC article.
Real life long-term efficacy and safety of ixekizumab in moderate-to-severe psoriasis: A 192 weeks multicentric retrospective study-IL PSO (Italian landscape psoriasis).
Malagoli P, Dapavo P, Pavia G, Amoruso F, Argenziano G, Bardazzi F, Burlando M, Carrera CG, Damiani G, Dini V, Girolomoni G, Guarneri C, Loconsole F, Narcisi A, Sampogna F, Travaglini M, Costanzo A. Malagoli P, et al. Among authors: travaglini m. Dermatol Ther. 2022 Aug;35(8):e15608. doi: 10.1111/dth.15608. Epub 2022 Jun 8. Dermatol Ther. 2022. PMID: 35638250
Real-life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52-week multicentre retrospective study-IL PSO (Italian landscape psoriasis).
Narcisi A, Valenti M, Gargiulo L, Ibba L, Amoruso F, Argenziano G, Bardazzi F, Burlando M, Carrera CG, Damiani G, Dapavo P, Dini V, Franchi C, Girolomoni G, Guarneri C, Loconsole F, Sampogna F, Travaglini M, Malagoli P, Costanzo A. Narcisi A, et al. Among authors: travaglini m. J Eur Acad Dermatol Venereol. 2023 Jan;37(1):93-103. doi: 10.1111/jdv.18594. Epub 2022 Oct 5. J Eur Acad Dermatol Venereol. 2023. PMID: 36156312 Free PMC article.
Brodalumab for the treatment of plaque psoriasis in a real-life setting: a 3 years multicenter retrospective study-IL PSO (Italian landscape psoriasis).
Gargiulo L, Ibba L, Malagoli P, Amoruso F, Argenziano G, Balato A, Bardazzi F, Burlando M, Carrera CG, Damiani G, Dapavo P, Dini V, Fabbrocini G, Franchi C, Gaiani FM, Girolomoni G, Guarneri C, Lasagni C, Loconsole F, Marzano AV, Megna M, Sampogna F, Travaglini M, Costanzo A, Narcisi A. Gargiulo L, et al. Among authors: travaglini m. Front Med (Lausanne). 2023 Jul 3;10:1196966. doi: 10.3389/fmed.2023.1196966. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37469659 Free PMC article.
A risankizumab super responder profile identified by long-term real-life observation-IL PSO (ITALIAN LANDSCAPE PSORIASIS).
Gargiulo L, Ibba L, Malagoli P, Amoruso F, Argenziano G, Balato A, Bardazzi F, Burlando M, Carrera CG, Damiani G, Dapavo P, Dini V, Fabbrocini G, Franchi C, Gaiani FM, Girolomoni G, Guarneri C, Lasagni C, Loconsole F, Marzano AV, Maurelli M, Megna M, Orsini D, Sampogna F, Travaglini M, Valenti M, Costanzo A, Narcisi A. Gargiulo L, et al. Among authors: travaglini m. J Eur Acad Dermatol Venereol. 2024 Jan;38(1):e113-e116. doi: 10.1111/jdv.19464. Epub 2023 Aug 29. J Eur Acad Dermatol Venereol. 2024. PMID: 37611277 No abstract available.
Effectiveness, Tolerability, and Drug Survival of Risankizumab in a Real-World Setting: A Three-Year Retrospective Multicenter Study-IL PSO (ITALIAN LANDSCAPE PSORIASIS).
Gargiulo L, Ibba L, Malagoli P, Amoruso F, Argenziano G, Balato A, Bardazzi F, Burlando M, Carrera CG, Damiani G, Dapavo P, Dini V, Franchi C, Gaiani FM, Girolomoni G, Guarneri C, Lasagni C, Loconsole F, Marzano AV, Maurelli M, Megna M, Orsini D, Sampogna F, Travaglini M, Valenti M, Costanzo A, Narcisi A. Gargiulo L, et al. Among authors: travaglini m. J Clin Med. 2024 Jan 16;13(2):495. doi: 10.3390/jcm13020495. J Clin Med. 2024. PMID: 38256629 Free PMC article.
Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis: a retrospective multicenter real-world experience on 5932 treatment courses - IL PSO (Italian landscape psoriasis).
Gargiulo L, Ibba L, Malagoli P, Balato A, Bardazzi F, Burlando M, Carrera CG, Damiani G, Dapavo P, Dini V, Gaiani FM, Girolomoni G, Guarneri C, Lasagni C, Loconsole F, Marzano AV, Megna M, Mercuri SR, Travaglini M, Costanzo A, Narcisi A. Gargiulo L, et al. Among authors: travaglini m. Front Immunol. 2024 Jan 11;14:1341708. doi: 10.3389/fimmu.2023.1341708. eCollection 2023. Front Immunol. 2024. PMID: 38274801 Free PMC article.
Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study - IL PSO (Italian landscape psoriasis).
Gargiulo L, Ibba L, Cascio Ingurgio R, Malagoli P, Amoruso F, Balato A, Bardazzi F, Brianti P, Brunasso G, Burlando M, Cagni AE, Caproni M, Carrera CG, Carugno A, Caudullo F, Cuccia A, Dapavo P, Di Brizzi EV, Dini V, Gaiani FM, Gisondi P, Guarneri C, Lasagni C, Licata G, Loconsole F, Marzano AV, Megna M, Mercuri SR, Musumeci ML, Orsini D, Ribero S, Ruffo Di Calabria V, Satolli F, Strippoli D, Travaglini M, Trovato E, Venturini M, Zichichi L, Valenti M, Costanzo A, Narcisi A. Gargiulo L, et al. Among authors: travaglini m. J Dermatolog Treat. 2024 Dec;35(1):2350760. doi: 10.1080/09546634.2024.2350760. Epub 2024 May 7. J Dermatolog Treat. 2024. PMID: 38714323 Free article.
29 results